Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 19/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.73 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | TTK | P33981 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018784 | 1.00 | LRRK2 (1.00) | LRRK2MAP3K9MKNK2JAK2TTK | |
| SCHEMBL18018932 | 0.94 | LRRK2 (0.88) | LRRK2MAP3K9MKNK2JAK2TTK | |
| SCHEMBL18018906 | 0.91 | LRRK2 (1.00) | LRRK2MAP3K9MKNK2TTK | |
| SCHEMBL17980593 | 0.90 | LRRK2 (0.81) | LRRK2MAP3K9MKNK2TTK | |
| SCHEMBL18018902 | 0.90 | LRRK2 (1.00) | LRRK2MAP3K9MKNK2TTK | |
| SCHEMBL22264283 | 0.89 | TTK (0.82) | LRRK2MAP3K9MKNK2JAK2TTK | |
| SCHEMBL22264303 | 0.89 | LRRK2 (0.79) | LRRK2TTK | |
| SCHEMBL21738312 | 0.87 | LRRK2 (0.78) | LRRK2MAP3K9MKNK2TTK | |
| SCHEMBL19921205 | 0.87 | LRRK2 (0.78) | LRRK2MAP3K9MKNK2JAK2TTK | |
| SCHEMBL24556862 | 0.86 | LRRK2 (0.77) | LRRK2MAP3K9MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709377-A2 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | Neuron23, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260011407-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | NEURON23 INC (US) | 2026-01-08 | — | — | US | claimed |
| EP-4565328-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | Neuron23, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| CN-120051279-A | Predictive biomarkers and their use for the treatment of parkinson's disease | 神经元23公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2024233854-A2 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | NEURON23, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024175076-A1 | USE OF LRRK2 AS THERAPEUTIC AND DIAGNOSTIC TARGET IN TUMOR THERAPY | 厦门大学 | 2024-08-29 | — | — | WO | claimed |
| CN-118526597-A | Application of LRRK2 inhibitor in resisting tumor | 厦门大学 | 2024-08-23 | — | — | CN | claimed |
| WO-2024030504-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | NEURON23, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| US-20230392206-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | NEURON23, INC. | 2023-12-07 | — | — | US | claimed |
| CN-116940353-A | Methods for the treatment and diagnosis of parkinson's disease associated with wild-type LRRK2 | 神经元23公司 | 2023-10-24 | — | — | CN | claimed |
| EP-4232024-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | Neuron23, Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| WO-2022093685-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | NEURON23, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| EP-4213843-B1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4709377-A2 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | Neuron23, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12559491-B2 | Modified imidazopyridines as glucosylceramide synthase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-24 | — | — | US | disclosed |
| WO-2022084210-A1 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022060764-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022060763-A2 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-03-24 | — | — | WO | disclosed |
| EP-3965750-A1 | CANCER STRATIFICATION AND TREATMENT BASED ON INHIBITION OF NOD-2 | Garvan Institute of Medical Research (AU) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | LRRK2 2887/4885MAP3K9 4668/4885MKNK2 4409/4885 |
| US-12559491-B2 | Modified imidazopyridines as glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | LRRK2 2236/4885MAP3K9 4580/4885MKNK2 4629/4885 |
| US-20260011407-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | LRRK2, PARK7, BMP2K | LRRK2 1/4885MAP3K9 1684/4885MKNK2 667/4885 |
| US-20230392206-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | LRRK2, PARK7, PINK1 | LRRK2 1/4885MAP3K9 352/4885MKNK2 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.